Abstract. Microtubule-associated protein 2 (MAP2), a protein linked to the neuronal cytoskeleton in the mature central nervous system (CNS), has recently been identified in glial precursors indicating a potential role during glial development. In the present study, we systematically analyzed the expression of MAP2 in a series of 237 human neuroepithelial tumors including paraffin-embedded specimens and tumor tissue microarrays from oligodendrogliomas, mixed gliomas, astrocytomas, glioblastomas, ependymomas, as well as dysembryoplastic neuroepithelial tumors (DNT), and central neurocytomas. In addition, MAP2-immunoreactive precursor cells were studied in the developing human brain. Three monoclonal antibodies generated against MAP2A-B or MAP2A-D isoforms were used. Variable immunoreactivity for MAP2 could be observed in all gliomas with the exception of ependymomas. Oligodendrogliomas exhibited a consistently strong and distinct pattern of expression characterized by perinuclear cytoplasmic staining without significant process labeling. Tumor cells with immunoreactive bi-or multi-polar processes were mostly encountered in astroglial neoplasms, whereas the small cell component in neurocytomas and DNT was not labeled. These features render MAP2 immunoreactivity a helpful diagnostic tool for the distinction of oligodendrogliomas and other neuroepithelial neoplasms. RT-PCR, Western blot analysis, and in situ hybridization confirmed the expression of MAP2A-C (including the novel MAP2ϩ13 transcript) in both oligodendrogliomas and astrocytomas. Double fluorescent laser scanning microscopy showed that GFAP and MAP2 labeled different tumor cell populations. In embryonic human brains, MAP2-immunoreactive glial precursor cells were identified within the subventricular or intermediate zones. These precursors exhibit morphology closely resembling the immunolabeled neoplastic cells observed in glial tumors. Our findings demonstrate MAP2 expression in astrocytic and oligodendroglial neoplasms. The distinct pattern of immunoreactivity in oligodendrogliomas may be useful as a diagnostic tool. Since MAP2 expression occurs transiently in migrating immature glial cells, our findings are in line with an assumed origin of diffuse gliomas from glial precursors.
INTRODUCTION
Immunohistochemistry has become an important tool for the differential diagnosis of tumors of the central nervous system (CNS) (1) . For example, immunoreactivity for the glial fibrillary acidic protein (GFAP) can consistently be observed in astrocytic and ependymal tumors. In oligodendrogliomas, GFAP expression is highly variable and restricted to special subtypes of tumor cells, namely the gliofibrillary oligodendrocytes and the minigemistocytes (2) . Unfortunately, there is no immunohistochemical marker available that specifically and reliably labels the major neoplastic cell type in oligodendrogliomas, i.e. the typical clear cell with a rounded hyperchromatic nucleus and an artifactually swollen cytoplasm that creates the characteristic honeycomb appearance of these tumors on routinely processed paraffin sections. These cells are frequently positive for protein S100 and the HNK1 (anti-Leu-7) carbohydrate epitope. However, neither expression of S100 nor of HNK1 is specific for oligodendrogliomas since both antigens are widely expressed in many other neuroectodermal tumors. Although differentiation antigens specifically associated with normal oligodendrocytes would represent candidates for the identification of oligodendrogliomas, so far none of these antigens has gained significance as a diagnostically useful marker. These antigens are either not expressed by neoplastic oligodendrocytes (e.g. myelin basic protein), or expressed in only a minority of cases, such as myelinassociated glycoprotein, galactolipids, proteolipid protein, and 2Ј-3Ј-cyclic nucleotide-3Ј-phosphatase (2) . The availability of a specific immunohistochemical marker for oligodendrogliomas would be of major clinical importance since these tumors respond far better to adjuvant chemotherapy than astrocytic gliomas (3) .
Expression of the microtubule-associated protein 2 (MAP2) is precisely regulated during brain development and maturation (4) (5) (6) . In the adult mammalian brain, neurons consistently express high molecular weight isoforms (MAP2A-B), and low molecular weight isoforms (MAP2C-D). The high molecular weight isoforms of II  III  IV  II  III  II  III  II  III  I  II   25  23  41  31  37  18  26  11  7 The monoclonal antibody, AP14, directed against the high molecular weight isoforms MAP2A/B was used for immunoblotting on 3.6%-15% SDS-PAGE. Lanes 1 and 2: oligodendrogliomas; Lanes 3 and 4: white and gray matter, respectively, of an epilepsy control patient without neoplastic lesion. Forty g of total protein extract was loaded per lane. Note that both tumors express the MAP2A/B isoforms. B: The monoclonal antibody, AP18, directed against high and low molecular weight isoforms (MAP2A-D) was used. The representation of lanes is identical to (A). In both tumors, the MAP2C isoform could be specifically visualized at ϳ70 kDa. Note the lack of MAP2 isoforms in white matter (lane 3).
MAP2 are essential for the dendritic development of neurons, and antibodies against these forms are used as neuronal markers. The low molecular weight isoforms of MAP2 lack the central portion of the high molecular weight isoforms, thus antibodies directed against N-and C-terminal domains of MAP2 likely detect all MAP2 isoforms (7) . In addition, these forms are also found in axons and glial cells and are subjected to phosphorylation, which is more pronounced during early development (8) . The significance of MAP2 phosphorylation is related to control of dynamic instability and disassembly of microtubules. Thus, monoclonal antibody AP18 is of particular interest since immunological recognition and phosphorylation depends on a proline-dependent kinase acting on ser136 near the n-terminal end (9) .
During human CNS development, oligodendroglial precursor cells have recently been shown to transiently produce an alternatively spliced MAP2 isoform that includes exon 13 (MAP2ϩ13) (10) , suggesting MAP2ϩ13 as a potential marker for oligodendroglial precursor cells. However, a transient expression in astroglial precursors/radial glia appears likely. These data render MAP2 potentially useful as a marker for immature and/or neoplastically transformed glial cells. We therefore became interested in studying the expression of MAP2 in human gliomas and to evaluate its potential use in the differential diagnosis of these tumors. Here, we report that MAP2, including the MAP2ϩ13 isoform, is frequently expressed in neoplastic cells of human gliomas. In particular, oligodendrogliomas are strongly MAP2-immunoreactive. Interestingly, MAP2-positive precursor cells with morphological features similar to MAP2-positive glioma cells are present in the subventricular and intermediate zones of the developing human brain but not in normal adult CNS. These findings are in line with the hypothesis that diffuse gliomas may arise from immature glial precursor cells.
MATERIALS AND METHODS

Patients
Surgical specimens from 237 patients with neuroepithelial tumors were used for this study (Table) . All tumors were retrieved from the archives of the Department of Neuropathology at the University of Bonn or the Department of Neuropathology at the Heinrich-Heine-University of Düsseldorf. MAP2 expression was also examined during the fetal and early postnatal development using specimens from 6 immature human brains obtained at autopsy (age range: 20 wk of gestation to 10 postnatal months). In addition, specimens from normal adult brain obtained at autopsy from 5 patients without neurological or psychiatric disorders (age range: 30-69 yr) were studied.
Immunohistochemistry and Antibody Specificity
We used 3 monoclonal antibodies that recognize different isoforms of MAP2. A monoclonal antibody AP14 directed against MAP2A/B recognizes MAP2 mainly in the somatodendritic part of normal and healthy neurons (11, 12) , whereas MAP2C-D is detected by monoclonal antibodies AP18 and C (6, 7, 11) . The difference between clone C and AP18 is that the latter reacts with a phosphorylated ser136 near the N-terminal end, while immunoreactivity of monoclonal antibody C is independent of the MAP2 phosphorylation state (9, 13). All MAP2 antibodies have been characterized previously in several studies and in different species (13, 14) .
To further characterize MAP2-immunoreactive cells, we used antibodies directed against protein S100, GFAP, synaptophysin (Dako, Glostrup, Denmark), or neurofilament proteins of low, medium, and high molecular weight (15) . Proliferation activity was determined with the MIB1 monoclonal antibody (Dako) against the proliferation-associated nuclear antigen Ki-67.
Immunohistochemistry was carried out on routinely processed tissue specimens using the avidin-biotin method (Vector Labs, Burlingame, CA) with 3Ј3Ј-diaminobenzidine as chromogen, as described before (16) . A subset of tumors was analyzed by staining sections from a glioma tissue array that carried representative tumor areas from 73 gliomas. For the glioma tissue microarray, 3 cylindrical blocks, 1-mm diameter, with representative areas from each tumor were subsequently arrayed using a Beecher Instruments arrayer (Gene Micro-Array Technology, Silver Spring, MD). Each array also contained normal specimens either from adjacent intact nervous tissue, if available, or from age-matched patients with no neurological disease, which served as an internal control in subsequent immunocytochemical stainings. Five-m sections from these tissue microarray blocks were used for immunocytochemistry.
All tumor specimens were fixed overnight in 4% buffered formalin and embedded in paraffin. The autopsy brains were fixed for 1 or 2 wk in 4% buffered formalin. Tissue sections were cut at 4 m with a microtome (Microm, Heidelberg, Germany), stretched in water at 60ЊC, and mounted on slides coated with 3-aminopropyltriethoxysilane (DAKO, Glostrup, Denmark). The slides were air-dried in an incubator at 37ЊC over night. Microwave pretreatment was used for the immunohistochemical reactions with antibodies against MAP2, Ki-67, and neurofilament proteins.
Colocalization of MAP2 and Other Marker Proteins
Double staining was carried out on 30 oligodendrogliomas, oligoastrocytomas and astrocytomas. For colocalization of MAP2 (antibody C) with S100 or GFAP, double immunofluorescence was used with both primary antibodies being processed in parallel. The MAP2 antibody was detected with a biotinylated secondary antibody followed by a Texas Red conjugated avidin complex (Vector Labs). The polyclonal antibodies to S100 and GFAP were visualized with a fluorescein-labeled secondary antibody (Sigma, St. Louis, MO). Double staining with the monoclonal MAP2 and Ki-67 antibodies was performed sequentially, using the same fluorescent dyes as described above. The double-stained sections were evaluated by confocal laser scanning microscopy (Leica TCS NT) using the dual channel imaging technique (krypton argon laser with emission of 488 nm for fluorescein and 568 nm for Texas Red), which permitted the simultaneous detection of both dyes.
Immunoblotting
The specificity of the immunohistochemical staining for MAP2 obtained in gliomas and normal brain tissue with the antibodies AP14, AP18, and ClonC was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) immunoblotting of selected cases. Seven snap-frozen specimens obtained from 5 patients were used, including normal gray and white matter (n ϭ 2, each) as well as oligodendrogliomas (n ϭ 3). Tissue samples were prepared according to previously published protocols (4) . From each specimen, 40 g of protein lysate was separated by SDS-PAGE on 3.6%-15% gradient gels. The gels were either stained with Coomassie Blue (Fluka, Buchs, Switzerland) or blotted onto a nitrocellulose membrane (BA-S 85, Schleicher & Schuell, Düsseldorf, Germany). The membranes were subsequently incubated in a solution of 10% normal horse serum to inhibit nonspecific antibody binding, followed by the incubation with MAP2 AP14, AP18, or ClonC antibodies. Blots were then incubated with secondary antibodies (rabbit-antimouse Ig conjugated with peroxidase; P260, Dako) at a concentration of 1 g/ml for 2-5 h, and immunoreactivity was visualized with 4-chloro-1-naphtol as chromogen.
In Situ Hybridization
In situ hybridization was carried out with digoxigenin (DIG) labeled in vitro transcribed cRNA probes using a slightly modified version of a previously described protocol (17) . In brief, primers specific for human MAP2A/B (5Ј-CAG CTG AAG CCC AGG CA-3Ј, 5Ј-TCT GGA GAC TGT GCT AGG TTC CT-3Ј) and MAP2C (5Ј-TGC CAT CTT GGT GCC GA-3Ј, 5Ј-CTT GAC ATT ACC ACC TCC AGG T-3Ј) were used to generate PCR products of 359 bp (MAP2A/B) and 370 bp (MAP2C) from a human hippocampal cDNA template (18) automated thermocycler (Uno Block, Biometra, Gottingen, Germany) using 36 cycles at 94ЊC for 30 s, 58ЊC for 40 s, and 72ЊC for 40 s. Significant homologies of the amplified MAP2A/B sequence with other previously characterized genes were excluded by performing a BLASTN search. The amplified MAP2C fragment also binds to MAP2A/B, which requires the staining patterns obtained for MAP2C and MAP2A/B to be subtracted. The respective PCR products served as templates for separate second round amplifications. Here, either one of the outlined MAP2 forward or reverse primers modified by an attached T7-RNA polymerase recognition site (5Ј-AAA CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT AGG CGCϪ3Ј) was used. PCR products served as templates (10.0 ng/l) for transcription. Sense and anti-sense cRNA probes were labeled by DIG and labeling efficacy was tested on dot blots (DIG RNA labeling kit, Boehringer Mannheim, Mannheim, Germany). Sense transcripts were used as controls. Cryostat sections of tumor samples (14 m) (n ϭ 3) and control brains (n ϭ 3) were prepared and hybridized with the DIG labeled cRNA probes (1:40 in hybridization buffer) at 57ЊC overnight. Hybridized sections were washed in 5ϫ SSC for 5 minutes and in 0.2ϫ SSC for 1 h (at 57ЊC each), blocked, DIGlabeled, and developed in detection buffer (175 mg/ml 5-bromo-4-chloro-3-indolyl-phosphate, 500 mg/ml levamisole, 340 mg/ml nitro blue tetrazolium chloride).
Reverse Transcription (RT)-PCR
Total RNA was extracted from snap-frozen surgical specimens (gliomas n ϭ 10; controls n ϭ 3) using TRIZOL reagent according to the manufacturer's protocol (Life Technologies, Carlsbad, CA). RNA extraction was followed by DNAse treatment. For reverse transcription, 10.0 g of total RNA was used as template. Reverse transcription was carried out as follows: RNA and oligo(dT) primer (100 ng/l) were simultaneously incubated at 80ЊC for 3 min and then chilled on ice. RT was performed in a total reaction volume of 30.0 l containing 6.0 l of 5ϫ first strand buffer (Life Technologies), 250 M dNTPs, 10 mM DTT, 150 mM KCl, 10 mM MgCl 2 , 1.0 l RNAsin, 42.0 U AMV-RT (Seikagaku Kogya, Tokyo). Reverse transcription was carried out at 42ЊC for 1.5 h. Amplification of the MAP2ϩ13 isoform proceeded with the following primers: 5Ј-AAT CAG CTC TGG CTC CCA GTG-3Ј and 5Ј-GGA GAA TGG AGG AAG GTC TTG G-3Ј (10). Amplification was carried out in a total reaction volume of 10 l containing 10 ng of cDNA, 200 M of each dNTP, 0.025 U Taq polymerase, 50 mM KCl, 10 mM TRIS-HCl pH 8.5, 1.5 mM MgCl 2 , 0.01% gelatin, and 0.5 M of each primer. Amplification was performed for 32 cycles of 30 s at 94ЊC, 40 s at 56ЊC, and 50 s at 72ЊC. Following RT-PCR, the PCR product was separated by agarose gel electrophoresis, followed by visualization of the PCR products with ethidium bromide under fluorescent light.
RESULTS
Specificity of the MAP2 Antibodies
The 3 antibodies against MAP2 used in this study detect different isoforms of the protein: AP14 is directed against MAP2A-B, whereas AP18 and clone C additionally detect the low molecular weight isoforms MAP2C-D. Antibody specificity was previously demonstrated by Western blot analysis (4) and confirmed here on protein extracts from human gray and white matter, as well as from selected oligodendroglioma cases (Fig. 1 ).
MAP2 Expression in the Adult Human Brain and During Brain Development
In normal adult brain tissue, all MAP2 antibodies showed intense labeling of neuronal dendrites and neuronal cell bodies (Fig. 2D) , whereas mature astrocytes, oligodendrocytes (Fig. 3D) , and ependymal cells never stained positive. Immunostaining of sections from immature human brain at the twentieth week of gestation revealed intense MAP2 labeling of the majority of neural precursor cells in the subventricular zone ( Fig. 2A, B) . Cellular processes were only sparsely visible in precursor cells of the subventricular zone ( Fig. 2A) . These cells showed a characteristic small and rounded cell morphology, similar to that observed in oligodendrogliomas (Fig.  3B, F) . Within the intermediate zone of the same developmental stage, substantial numbers of MAP2-immunoreactive precursor cells could still be seen (Fig. 2B) . Many of these cells demonstrated bi-or multi-polar processes, comparable to those observed in astrocytomas. Within the cortical plate, the majority of neuronal precursor cells did not exhibit MAP2 immunoreactivity during early maturation (20 to 29 wk of gestation). However, at postnatal stages, MAP2 was consistently expressed in cortical neurons but not in astroglia or oligodendrocytes of the white matter (Figs. 2D, 3D ).
MAP2 Expression in Oligodendrogliomas
The tumor cells in low-grade oligodendrogliomas (WHO grade II) were consistently labeled with antibodies directed against MAP2A-B or MAP2A-D isoforms (Fig.  3B, C) . Most characteristically, the perinuclear cytoplasm of the tumor cells was intensely stained, whereas labeling of processes was sparse. This pattern was found in all oligodendrogliomas as well as oligodendroglial components of oligoastrocytomas analyzed (n ϭ 49). In addition, MAP2-immunoreactive residual neurons with prominent, arborizing processes were frequently detected between infiltrating tumor cells. However, their distinct morphology rendered the differentiation from MAP2-positive glioma cells easy. Consistent MAP2 immunoreactivity was also present in anaplastic oligodendrogliomas and anaplastic oligoastrocytomas of WHO grade III (n ϭ 63) (Fig. 3E, F) . However, in malignant tumors the cellular labeling was often blurred due to increased cellularity and diffuse matrix staining.
In situ hybridization confirmed the expression of the high molecular weight isoform MAP2A/B in human oligodendrogliomas (Fig. 4A) , as well as in differentiated pyramidal neurons of the adult human hippocampus (Fig. 4D) . The sequence of MAP2 did not allow the generation of MAP2C-specific oligonucleotides. However, probes recognizing MAP2A-C showed specific granular labeling in all tumor samples examined (Fig.  4B, E) . With respect to the data obtained from our Western blot analysis, the results would be compatible with the expression of both low and high molecular weight MAP2 isoforms in human gliomas.
Using confocal laser scanning microscopy, double labeling experiments for GFAP and MAP2 showed no colocalization of these marker proteins in gliomas (Fig. 5A-C) . In contrast, MAP2 and S-100 protein were frequently co-expressed in oligodendroglial tumor cells (Fig. 5D-F) . The proliferative activity of MAP2-immunoreactive oligodendroglial tumor cells was confirmed by double labeling experiments for MAP2 and Ki-67 (Fig. 5G-I ). Antibodies against neuronal marker proteins, including low, medium and high molecular weight neurofilament as well as synaptophysin, did not label oligodendroglial tumor cells in our series (data not shown).
MAP2 Immunoreactivity in Astrocytic Gliomas and Ependymomas
In addition to oligodendrogliomas and oligoastrocytomas, we also studied a large series of diffusely infiltrating astrocytic tumors, including diffuse astrocytomas (WHO grade II), anaplastic astrocytomas (WHO grade III), and glioblastomas (WHO grade IV), as well as different types of ependymal neoplasms (Table) . All astrocytic tumors contained a subpopulation of MAP2-positive/GFAP-negative tumor cells. The percentage of MAP2-positive glioma cells was, however, more variable compared to oligodendrogliomas, and the morphology of the labeled cells was distinct from that seen in oligodendrogliomas. Astrocytoma cells displayed bi-or multi-polar processes (Fig. 6B, D) . None of the ependymal tumors analyzed in this study showed a significant fraction of MAP2-immunoreactive tumor cells.
MAP2 Immunoreactivity in the Differential Diagnosis of
Neuroepithelial Tumors with ''Oligodendroglia-Like'' Clear Cells
The differential diagnosis between oligodendrogliomas and certain other rare neuroepithelial tumors with clear cell morphology, including central neurocytomas, DNT, and clear cell ependymomas, can be difficult. With respect to MAP2 expression, only oligodendrogliomas showed strong cellular labeling within the majority of tumor cells (Fig. 7A) . In central neurocytomas, the neuropil matrix of the tumor was stained, whereas the clear cell cytoplasm of tumor cells did not react with MAP2 antibodies (Fig. 7D) . Similarly, the small oligodendroglial-like tumor cells in DNTs did not show any immunoreactivity for MAP2, whereas floating neurons were consistently labeled (Fig. 7E) . Investigation of 2 cases of clear cell ependymomas showed no tumor-cell-associated MAP2 immunoreactivity (Fig. 7B, C) , a finding similar to the results obtained for other types of ependymomas.
Expression of the MAP2ϩ13 Isoform in Gliomas
According to Shafit-Zagardo et al (10) , immature human oligodendrocytes transiently express the novel MAP2ϩ13 isoform. We therefore analyzed the expression of the MAP2ϩ13 splice variant by reverse transcription-PCR in normal adult brain and selected gliomas. Whereas none of the adult control brains showed the MAP2ϩ13-specific RT-PCR product that includes exon 13, all investigated tumors, including oligodendrogliomas and astrocytomas (n ϭ 7), expressed this alternatively spliced variant (Fig. 8 ).
DISCUSSION
Our study demonstrates that the microtubule-associated protein MAP2 is abundantly expressed by neoplastic glial cells in human oligodendrogliomas and astrocytomas. We further show that that these gliomas express various MAP2 isoforms, including the high molecular weight isoforms MAP2A-B that are thought to be confined to mature neurons, and the MAP2ϩ13 splice variant, which has recently been identified in oligodendroglial precursors during early brain development (10) . Oligodendrogliomas exhibit the strongest immunoreactivity for MAP2. Immunohistochemical reactions highlight the typical clear-cell component of these tumors. MAP2 immunostaining may therefore be useful as a marker for the differential diagnosis of oligodendroglioma from other gliomas and from neuroepithelial tumors with clearcell morphology, such as DNT, central neurocytomas, and clear cell ependymomas.
Plasticity of MAP2 Expression in the CNS
The different MAP2 isoforms are known to be differentially expressed either in neurons (i.e. MAP2A-B) or in glia (i.e. MAP2C) (19, 20) . The expression is also differentially regulated during brain development (10, 21) . Whereas glial cells express MAP2 only during early differentiation, the major source of MAP2 in the mature brain is neuronal. Although experimental evidence has not yet been provided, functional mechanisms of MAP2 in neural precursor cells may be related to process outgrowth by modulating microtubule assembly/stabilization (22) . Our data also indicate that phosphorylated MAP2 is present in neoplastic glial cells (as detected by AP18). Phosphorylated MAP2 binds to microtubules and may functionally modify the cytoskeleton by scavenging tubulin, thereby reducing microtubule polymerization (10) .
An interesting finding is the morphological similarity between MAP2-immunoreactive precursor cells and MAP2-positive glioma cells. In particular, the morphology of MAP2-positive tumor cells in oligodendrogliomas closely resembles that of the small precursor population in the subventricular zone of the developing human brain (compare Fig. 2 with Fig. 3 ). The lack of distinct processes characterizes the morphology of both cell populations. Astrocytic tumors usually contain neoplastic cells with bi-or multi-polar fibrillar processes, some of which reveal MAP2 immunoreactivity. Morphologically, these tumor cells resembled MAP2-positive cells observed in the intermediate zone into which glial precursor cells migrate. As a matter of fact, glial precursor cells are among the most actively migrating cell populations, a feature they share with diffusely infiltrating glioma cells. It remains to be studied whether MAP2 expression may be important for cell migration and/or invasion. Furthermore, the observed morphological similarities between MAP2-positive glioma cells and MAP2-positive glial precursors are compatible with the hypothesis that gliomas arise from immature glial precursor cells rather than from differentiated astrocytes or oligodendrocytes. A recent study demonstrating expression of the oligodendrocyte progenitor-associated molecules NG2 and plateletderived growth factor receptor-␣ in a small series of gliomas supports this hypothesis (23) . Neural stem cells with a potential to generate different glial and neuronal lineages are still present in limited numbers within the mature and senescent brain (24, 25) , although the pool of self renewing cells may decrease with age (26) . Thus, the preferential manifestation of gliomas in adults between 40 and 70 yr does not exclude the possibility that these tumors originate from neoplastically transformed glial precursors. Additional experiments will be needed to resolve this intriguing issue.
Oligodendrogliomas Consistently Express MAP2: A Useful Diagnostic Tool?
Within our large series of diffuse brain tumors, oligodendrogliomas as well as the oligodendroglial components in oligoastrocytomas showed a consistent immunoreactivity for MAP2. In paraffin-embedded surgical specimens, their cellular morphology is usually defined by rounded hyperchromatic nuclei embedded in an artefactually swollen (clear) cytoplasm with well-defined cell borders and sparse processes. The resulting tissue architecture has been described as a honeycomb structure (Fig. 2) . antigen, meaning that they belong to the proliferative fraction of tumor cells within oligodendrogliomas.
The differential diagnosis of oligodendrogliomas includes astrocytic gliomas, mixed gliomas, and a number of rare neuroepithelial tumors such as clear cell ependymoma, DNT, and central neurocytoma. These latter entities share with oligodendrogliomas the presence of neoplastic cells with uniform round nuclei and clear cytoplasm. Although these tumor types can be readily distinguished at the ultrastructural level, their distinction by routine H&E can be extremely difficult (2) . We have evaluated the expression of MAP2 in these tumors and found that only the oligodendrogliomas showed consistent and strong labeling of tumor cells with a characteristic perinuclear pattern of immunoreactivity. In central neurocytomas and DNT, the small and clear cell population never showed any immunoreactivity for MAP2, whereas its neuronal components (the neuropil islands or floating neurons) strongly stained for MAP2. Furthermore, none of the ependymomas used in this study, including 2 clear cell variants, were immunoreactive for MAP2.
Five of the glioblastomas included in this study showed a focal oligodendroglial component. A recent study suggested that such tumors may be associated with a somewhat better prognosis and a higher likelihood for a positive response to polychemotherapy than ordinary glioblastomas (27) . Similar to the findings in oligoastrocytomas, the focal oligodendroglial component in these 5 glioblastomas was strongly MAP2-positive, a finding that underlines the usefulness of MAP2 immunostaining for the recognition of neoplastic oligodendroglial cells.
